DNAprint Genomics (DNAG)

[Virgil Hilts]

Correct me if I am wrong, Doc, but hasn't the pps gone up since since the Statinome PR came out? It seems to me that investors have been buying it and driving the price up. I have said all along that DNAG is a high-risk penny stock with a lousy track record, but great potential. Recently, the risk has gone down a notch, IMO. The track record is still lousy and the risk is still high, and the potential keeps getting better. IMHO I think the pps will continue to rise this year as the revenues continue to rise, the risk decreases, and the products in the pipeline continue their march to market.

Virgil